. NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–45.
2.
. MoonCA, JesingerDK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. Br J Clin Pract1991; 45: 259–62.
3.
. AlvarezE, BobesJ, GomezJC, SacristanJA, CanasF, CarrascoJL, et al.; EUROPA Study Group. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. Eur Neuropsychopharmacol2003; 13: 39–48.
4.
. BobesJ, RejasJ, Garcia-GarciaM, Rico-VillademorosF, Garcia-PortillaMP, FernandezI, Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res2003; 62: 77–88.
5.
. SussmanN. Choosing an atypical antipsychotic. Int Clin Psychopharmacol2002; 17 (suppl 3): S29–33.
